key: cord-0916559-gca9vjnz authors: Mariotto, Sara; Carta, Sara; Dinoto, Alessandro; Lippi, Giuseppe; Salvagno, Gian Luca; Masin, Laura; Alberti, Daniela; Marignier, Romain; Ferrari, Sergio title: Is there a correlation between MOG‐associated disorder and SARS‐CoV‐2 infection? date: 2022-03-14 journal: Eur J Neurol DOI: 10.1111/ene.15304 sha: 2d4a61fd30a1fc70287b0dd32ff00c68070c2d42 doc_id: 916559 cord_uid: gca9vjnz BACKGROUND AND PURPOSE: Anti‐myelin oligodendrocyte glycoprotein antibodies (MOG‐Abs) distinguish a group of inflammatory disorders which can be preceded by specific or non‐specific infections. A few single cases have been reported in association with SARS‐CoV‐2 infection, but a specific study on the correlation between COVID‐19 and myelin oligodendrocyte glycoprotein (MOG)‐associated disorder (MOGAD) has not yet been performed. The aim of this study was to determine the impact of the pandemic on this condition. METHODS: We analysed SARS‐CoV‐2 serology in patients newly diagnosed with MOGAD (1 August 2020 to 31 May 2021). MOG‐Ab‐seronegative age‐ and time‐matched subjects were used as controls. SARS‐CoV‐2 immunoglobulin G (IgG) levels were analysed using an anti‐SARS‐CoV‐2 US Food and Drug Administration‐approved ELISA assay and confirmed with a trimeric anti‐SARS‐CoV‐2 S1/S2 IgG immunochemiluminescent test, concomitantly assaying the anti‐receptor binding domain (RBD) of spike protein IgG and anti‐RBD total Ig. We actually compared the number of cases referred in each of the last 3 years. RESULTS: Presence of SARS‐CoV‐2 IgG antibodies was more common (12/30, 40%) in MOGAD patients than in controls (6/30, 20%), although the difference was not significant (p = 0.16; odds ratio 2.67, 95% confidence interval 0.85–9.17). The most common clinical presentations of MOGAD SARS‐CoV‐2‐seropositive patients included optic neuritis (n = 6) and myelitis (n = 3). The number of diagnosed cases increased over the last 3 years, in particular, when including cases referred to us before the COVID‐19 pandemic, in the initial phase of the first wave and in the late phase of the second wave (n = 9, rate 10.6% in 2019; n = 13, rate 12.3% in 2020; n = 15, rate 14.7% in 2021). CONCLUSION: Our findings provide preliminary data on SARS‐CoV‐2 as a potential trigger of MOGAD. Anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) define a distinct group of inflammatory central nervous system disorders of both adults and children with a clinical phenotype compatible with acute disseminated encephalomyelitis (ADEM), optic neuritis, myelitis, brainstem syndrome and encephalitis, which evolve in a monophasic or relapsing course [1, 2] . Attacks can be preceded by infections which have been proposed as potential triggers of MOG-associated disorder (MOGAD) [3] . Antecedent symptoms are usually referred to as non-specified respiratory or feverish infection, but in some patients a specific infectious agent can be identified, supporting the occurrence of infection-associated immune response [3] . A few case reports of MOGAD occurring concomitantly or after SARS-CoV-2 infection have been described [4] [5] [6] [7] [8] [9] [10] , however, the possible correlation between these two conditions has not yet been investigated systematically. The aim of this study was to analyse the impact of SARS-CoV-2 infection on MOGAD by (i) determining the frequency of SARS-CoV-2 infection in newly diagnosed MOGAD through extensive serological analyses and (ii) analysing the number of MOGAD cases referred to our tertiary center during the COVID-19 pandemic in comparison to the pre-pandemic period. We retrospectively identified consecutive treatment-naive patients who tested MOG-IgG positive for the first time at our Laboratory The presence of MOG-Abs was analysed by two independent investigators (S.F., S.M.) at the Verona Neuropathology Laboratory using a recombinant live cell-based immunofluorescence assay with HEK293A cells transfected with full-length MOG (human MOG alpha-1 enhanced green fluorescent protein fusion protein), as previously described [2] . We analysed the number of MOGAD cases diagnosed in the last The study was approved by the local Bioethics Committee (Comitato SARS-CoV-2 IgG positivity was higher in MOG-Ab-seropositive patients (12/30, 40%) than in the MOG-Ab-seronegative controls (6/30, 20%), although the difference was not significant (p = 0.16; odds ratio 2.67, 95% confidence interval 0.85-9.17). The monthly distribution of SARS-CoV-2-seropositive cases in relation to MOG-Ab status is reported in Figure 1a . In this study, we analysed the possible correlation between SARS-CoV-2 infection and MOGAD by studying SARS-CoV-2 IgG serology in this condition and by comparing its incidence in different periods over the last years. The incidence of SARS-CoV-2 infection was compatible with the phenotypes previously described [1, 2] , with most of the patients presenting with optic neuritis and/or myelitis. By contrast, patients presenting with SARS-CoV-2-associated ADEM are unlikely to harbor MOG-Abs [11] . The predominance of encephalitis/encephalopathies recently reported might be the effect of a selection bias, since SARS-CoV-2 infection might be investigated predominantly in these conditions [4] [5] [6] 8, 10] . Our study has some relevant limitations including: (i) the small sample size of the analysed cohort, which might have influenced our findings, in particular the comparison between MOGAD SARS-CoV-2 IgG-seropositive and -seronegative cases (according to our data, the required sample size for further investigation, accounting for a 5% precision and 95% confidence interval, would be 369 MOG-Ab-positive and 246 MOG-Ab-negative patients, which would require a multicenter epidemiology-based study); (ii) the monocentric nature of our study; (iii) the inability to analyse other possible infectious triggers, such as influenza, the incidence of which nevertheless decreased during the pandemic [12] , because of the diagnostic restrictions that were in place during the pandemic; and (iv) the short follow-up, which prevents us from determining the impact of SARS-CoV-2 infection on the MOGAD disease course. To conclude, according to our data, SARS-CoV-2 infection might have a relationship with MOGAD, even in paucisymptomatic cases. Further multicenter prospective studies are necessary to confirm our findings and to determine the disease course of these patients. The data that support this study are available for sharing and further examination from the corresponding authors (S.M.) on reasonable requests. The data are not publicly available because they contain information that could compromise patients' consent. https://orcid.org/0000-0002-7806-3103 Alessandro Dinoto https://orcid.org/0000-0002-3249-4792 Sergio Ferrari https://orcid.org/0000-0003-3855-5135 Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome Two paediatric patients with encephalopathy and concurrent COVID-19 infection: two sides of the same coin? Post-COVID-19 encephalomyelitis MOG-associated encephalitis following SARS-COV-2 infection Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19 Myelin oligodendrocyte glycoprotein antibody encephalitis following severe acute respiratory syndrome coronavirus 2 in a pediatric patient Case report: myelin oligodendrocyte glycoprotein antibodyassociated relapse with COVID-19 CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19 Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis Decreased influenza activity during the COVID-19 pandemic -United States Is there a correlation between MOG-associated disorder and SARS-CoV-2 infection?